Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 2

Sponsor Class

OTHER 4INDUSTRY 2NIH 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 2Adenomatous Polyposis Coli 2Thrombocythemia, Essential 1Primary Myelofibrosis 1Precancerous Conditions 1Polycythemia Vera 1Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Leukemia, Myelomonocytic, Chronic 1Colorectal Neoplasms 1

Interventions

guselkumab 2Sulindac 2Eflornithine 2Celecoxib 2trifluridine tipiracil drug combination 1rofecoxib 1Oxaliplatin 1Nivolumab 1Leucovorin 1Fluorouracil 1Endoscopy 1Eicosapentaenoic Acid 1Duration of Therapy 1Docosahexaenoic Acids 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Adenomatous Polyposis Coli × Celecoxib × Clear all
NCT00151476 2024-09-04

Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients

Pfizer

Terminated
68 enrolled 22 charts
Gastrointestinal

Adenomatous Polyposis Coli

NCT00585312 2021-02-21

CHIP

Pfizer

Phase 3 Terminated
106 enrolled 10 charts
Gastrointestinal

Adenomatous Polyposis Coli

Data powered by HemOnc (CC BY 4.0) Colophon âš¡